Answers are grounded in this paper and cite their sources.
Commentary discusses mortality risks of sulphonylureas compared to metformin in type 2 diabetes, highlighting implications.
Current clinical guidelines in the USA and the UK recommend first-line glucose-lowering treatment with metformin monotherapy for glucose control in type 2 diabetes, where not contraindicated. Consequently, the proportion of people treated with sulphonylureas is decreasing. The purpose of this commentary is to discuss the risks and benefits associated with sulphonylurea monotherapy versus metformin monotherapy and the evidence that, in comparison with metformin, sulphonylureas cause increased harm to people with type 2 diabetes.
No takes yet. Share an insight, caveat, or question.
Holden et al. (2014) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: